Outlook Therapeutics, Inc., 2026-05-07
An SEC Form D private-offering notice from Iselin, NJ, a $5,000,000 filer-stated offering target in Biotech. Filed 2026-05-07. The source filing is one click away. For companies that filed this week, open the live feed.
What this filing says
Clinical-stage biopharmaceutical company developing LYTENAVA (bevacizumab-vikg), an ophthalmic formulation of bevacizumab for wet age-related macular degeneration and other retinal diseases.
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.
Other Form D filings from the same week
each with its own page and its own EDGAR source- Memoramedia Inc., 2026-05-13, $5M, Livingston, NJ
- Lighthouse Pharmaceuticals, Inc., 2026-05-07, $15.2M, Novato, CA
- Sentrimed, Inc., 2026-05-13, $1M, Mullica Hill, NJ
- AXOFT, INC., 2026-05-07, $34.2M, Cambridge, MA
- Skinny Flav INC, 2026-05-08, $300K, Howell, NJ
- Neopenda, PBC, 2026-05-07, $1.5M, Chicago, IL
The Monday digest, free
A summary of who raised money last week: the ones worth a call first, then every company that filed, by state and sector. One email, Monday mornings. No spam, unsubscribe anytime.
By subscribing you agree to our Terms and Privacy Policy.